2025
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
Wolf D, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, Investigators I, Symmans W, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin E, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van ‘t Veer L, Mukhtar R, Melisko M, Wallace A, Yeung K, Albain K, Robinson P, Lo S, Olopade F, Potter D, Beckwith H, Blaes A, Boughey J, Haddad T, Elias A, Isaacs C, Mitri Z, Kemmer K, Lu J, Lang J, Thomas A, Trivedi M, Hershman D, Meisel J, Kalinsky K, Vaklavas C, Williams N, Ellis E, Sanford A, Sanft T, Viscusi R, Arora M, Falkson C, Northfelt D, Murthy R, Haley B, Yung R, Mayer I, Khan Q, Edmiston K. Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precision Oncology 2025, 9: e2400776. PMID: 40526879, PMCID: PMC12184982, DOI: 10.1200/po-24-00776.Peer-Reviewed Original ResearchConceptsPCR ratePredicting pathologic complete responseTriple-negative breast cancerNeoadjuvant immunotherapyTumor gradeHormone receptor-positive early-stage breast cancerHuman epidermal growth factor receptor 2-negativeBreast cancerEarly-stage triple-negative breast cancerImmune-related adverse eventsControl armEarly-stage breast cancerMammaPrint-high riskHormone receptor-positivePathological complete responseResponse to IOI-SPY2 trialStandard of careER-lowComplete responseNeoadjuvant therapyReceptor-positiveHER2+I-SPY2Adverse eventsInterferon signaling and outcomes in triple-negative breast cancer (TNBC) in FinXX, CALGB 40603 (Alliance) and real-world clinico-genomic data.
Chumsri S, Liu Y, Deshmukh S, Carter J, Joensuu H, Leon-Ferre R, Zahrieh D, Boughey J, Ingle J, Couch F, Roussos Torres E, Lustberg M, Stover D, Sikov W, Partridge A, Carey L, Sledge G, Goetz M, Knutson K, Thompson E. Interferon signaling and outcomes in triple-negative breast cancer (TNBC) in FinXX, CALGB 40603 (Alliance) and real-world clinico-genomic data. Journal Of Clinical Oncology 2025, 43: 569-569. DOI: 10.1200/jco.2025.43.16_suppl.569.Peer-Reviewed Original ResearchTriple-negative breast cancerRecurrence-free survivalTumor-infiltrating lymphocytesLocation of tumor-infiltrating lymphocytesOverall survivalSignature scoreInterferon signalingAssociated with pathologic complete responseTriple-negative breast cancer patientsReal-world overall survivalPathological complete responseResidual cancer burdenTriple-negative breast cancer samplesClinical trial cohortAssociated with significant improvementsClinical outcome dataKaplan-Meier estimatesMann-Whitney UPotential key biomarkersMedian OSComplete responsePCR rateTNBC cohortPrognostic roleImmune desertImmune biomarkers as predictors of response to mosunetuzumab in previously untreated follicular (FL) and marginal zone lymphoma (MZL).
Milrod C, Chorzalska A, Morgan J, Pardo M, Raker C, Ollila T, Pelcovits A, McMahon J, Donnelly S, Carmody C, Dallesandro F, Matasar M, Huntington S, Dubielecka P, Olszewski A. Immune biomarkers as predictors of response to mosunetuzumab in previously untreated follicular (FL) and marginal zone lymphoma (MZL). Journal Of Clinical Oncology 2025, 43: 7063-7063. DOI: 10.1200/jco.2025.43.16_suppl.7063.Peer-Reviewed Original ResearchMarginal zone lymphomaCTLA-4 levelsComplete responseT cell activationCTLA-4T cellsImmune biomarkersNK cellsCytokine levelsInvestigator-initiated phase 2 trialMarkers of T-cell activationEffector memory T-cell subsetsIndolent B-cell lymphomaCD8+ T cellsMemory T cell subsetsInvestigation of combination therapyFlow cytometryCD8+ subsetsBaseline cytokine levelsCirculating NK cellsB-cell lymphomaT cell subsetsImmune cell subsetsMultiplex Luminex assaySystemic immune changesStudy EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results.
Mar N, Petrylak D, Hoimes C, Rosenberg J, Flaig T, Gourdin T, Barata P, Henry E, Bilen M, George S, Rao S, Assikis V, Burgess E, Lewis B, Srinivas S, Gorla S, Meng C, Zhu Y, O'Donnell P. Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results. Journal Of Clinical Oncology 2025, 43: 4583-4583. DOI: 10.1200/jco.2025.43.16_suppl.4583.Peer-Reviewed Original ResearchMedian event-free survivalPathological complete responseEvent-free survivalInvestigator assessmentEnfortumab vedotinEfficacy resultsOS ratesNeoadjuvant treatmentSafety profileFollow-upPathologic complete response ratePelvic lymph node dissectionEvent-free survival rateAntitumor activityLong-term follow-upCentral pathology reviewEstimated OS ratesNeoadjuvant treatment optionsLymph node dissectionMedian follow-upPhase 3 trialCT2-T4aN0M0Median OSConsistent with prior reportsComplete responseGene expression signatures (GES) derived from digital histology to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (CT) in ISPY2 and other trial/real world cohorts.
Howard F, Babu R, Dolezal J, Huo D, Borowsky A, Symmans W, Campbell M, Wolf D, Hirst G, Venters S, Asare A, Kanaparthi S, Blenman K, Shan N, Perou C, Esserman L, van t Veer L, Pusztai L, Nanda R, Pearson A. Gene expression signatures (GES) derived from digital histology to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (CT) in ISPY2 and other trial/real world cohorts. Journal Of Clinical Oncology 2025, 43: 587-587. DOI: 10.1200/jco.2025.43.16_suppl.587.Peer-Reviewed Original ResearchPathological complete responseLikelihood of pathologic complete responseGene expression signaturesHR statusPattern of lymphocyte infiltrationStandard of care CTPredicting pathologic complete responsePrediction of response to therapyHormone receptorsPathologic complete response predictionImprove treatment personalizationPre-treatment biopsiesTime of biopsyResponse to therapyBreast cancer subtypesEstrogen-regulated genesBenjamini-Hochberg correctionNeoadjuvant cohortNeoadjuvant CTYale cohortComplete responseNeoadjuvant chemotherapyPCR rateNodal stagingBreast cancer signaturesPredicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.
Tung N, Zhao F, DeMichele A, Prat A, Winer E, Wright J, Recht A, Weiss A, Tjoe J, Feldman S, Rocque G, Smith M, O'Sullivan C, Sardesai S, Villagrasa P, Badve S, Partridge A, Miller K, Carey L, Wolff A. Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial. Journal Of Clinical Oncology 2025, 43: 501-501. DOI: 10.1200/jco.2025.43.16_suppl.501.Peer-Reviewed Original ResearchPCR ratePredicting pathologic complete responseBreast cancerER statusPredictor of pCRAssociated with higher pCR ratesHER2+ breast cancerCycles of trastuzumabLow ER expressionPathological complete responseClinical stage IIAAssociated with high gradeRecurrence-free survivalHigh gradePCR scoreCN3 diseaseWeekly paclitaxelComplete responseNodal involvementProportion of cellsDiagnostic biopsyER expressionStage IIBClinicopathological factorsClinicopathological variablesStandard of Care Idecabtagene Vicleucel (Ide-cel) for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
Sidana S, Ahmed N, Akhtar O, Brazauskas R, Oloyede T, Bye M, Hansen D, Ferreri C, Freeman C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison M, Kitali A, Landau H, Mirza A, Patwardhan P, Qazilbash M, Usmani S, Patel K, Nishihori T, Ganguly S, Pasquini M. Standard of Care Idecabtagene Vicleucel (Ide-cel) for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis. Blood 2025 PMID: 40198886, DOI: 10.1182/blood.2024026216.Peer-Reviewed Original ResearchCAR-T cell therapyStandard of careIde-celComplete responseIdecabtagene vicleucelMultiple myelomaImmune effector cell-associated neurotoxicity syndromeClinical trialsMedian progression-free survivalHigh-risk cytogeneticsProgression-free survivalT-cell therapyTreatment-related mortalityRelapsed/refractory multiple myelomaMedian follow-upClinically significant infectionsCytokine release syndromeSignificant co-morbiditiesSignificant co-morbidityEffects of standard of careExtramedullary diseaseCAR-TMyeloid malignanciesPrimary malignancyMedian ageMultiplex Spatial Proteomic Analysis of HER2–Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response
Hennessy M, Cimino-Mathews A, Carter J, Kachergus J, Ma Y, Leal J, Solnes L, Denbow R, Abramson V, Carey L, Rimawi M, Specht J, Storniolo A, Valero V, Vaklavas C, Winer E, Krop I, Wolff A, Wahl R, Perez E, Huang C, Stearns V, Thompson E, Connolly R. Multiplex Spatial Proteomic Analysis of HER2–Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response. JCO Precision Oncology 2025, 9: e2400546. PMID: 40179327, PMCID: PMC11968088, DOI: 10.1200/po-24-00546.Peer-Reviewed Original ResearchConceptsPrediction of pathological complete responseHER2-positive breast cancerBreast cancerAbundant tumorHematoxylin and eosin and immunohistochemistryClinical trialsEstrogen receptor (ER)-negativeStromal tumor-infiltrating lymphocytesHuman epidermal growth factor 2 (HER2)-positive breast cancerPathological complete responseTumor-infiltrating lymphocytesEpidermal growth factor receptor signalingImmune cell activationDigital spatial profilingImmune-based biomarkersGeoMx Digital Spatial ProfilerNanoString GeoMx Digital Spatial ProfilingGrowth factor receptor signalingBaseline Ki67Baseline tumorsComplete responseER-negativeBasal-likeTumor biopsiesImmunological featuresA phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome
Garcia-Manero G, Gaddh M, Platzbecker U, Lindsley R, Larson S, Chevassut T, Fenaux P, Komrokji R, Lyons R, Al-Kali A, Jiang Y, Bothos J, Townsley D, Zeidan A. A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome. Annals Of Hematology 2025, 104: 1577-1585. PMID: 40153010, PMCID: PMC12031784, DOI: 10.1007/s00277-024-06081-4.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsDose-limiting toxicityPhase 1 studyPD-L1Adverse eventsUpregulation of programmed death ligand 1Marrow complete responseDeath-ligand 1Hypomethylating agent treatmentPrimary safety endpointProgression to AMLEvaluation of clinical outcomesComplete responseHematologic improvementIWG criteriaMyelodysplastic syndromeOpen-labelSecondary endpointsSafety endpointsClinical outcomesLimited efficacyPatientsLigand 1Agent treatmentOverall responseHMBOX1 reverses autophagy mediated 5-fluorouracil resistance through promoting HACE1-induced ubiquitination and degradation of ATG5 in colorectal cancer
Gao Y, Fu S, Peng Y, Zhou Y, Zhu J, Zhang X, Cai C, Han Y, Shen H, Zeng S. HMBOX1 reverses autophagy mediated 5-fluorouracil resistance through promoting HACE1-induced ubiquitination and degradation of ATG5 in colorectal cancer. Autophagy 2025, 21: 1556-1577. PMID: 40126194, DOI: 10.1080/15548627.2025.2477443.Peer-Reviewed Original ResearchColorectal cancer cellsColorectal cancerCancer cellsColorectal cancer tissuesColorectal cancer tissues of patientsLiquid chromatography-tandem mass spectrometryChromatography-tandem mass spectrometryFetal human colonProgression-free survivalClinical colorectal cancer tissuesFirst-line treatmentCell Counting Kit-8Cancer tissues of patientsPostoperative colorectal cancerCaspase 3Transmission electron microscopyCounting Kit-8Tissues of patientsMass spectrometryCleaved caspase 3Stable diseaseComplete responsePartial responseOverall survivalRegulation of chemoresistanceMachine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial
Zerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H, Boyaci C, Boman C, Poncet C, Ignatiadis M, Bai Y, Rimm D, Cameron D, Bonnefoi H, Bergh J, MacGrogan G, Foukakis T. Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial. Npj Breast Cancer 2025, 11: 23. PMID: 40055382, PMCID: PMC11889191, DOI: 10.1038/s41523-025-00730-1.Peer-Reviewed Original ResearchPathological complete responseAssociated with pathologic complete responseBreast cancerTriple-negativeCD8+ T cell expressionImmune infiltrate characterizationPretreatment tumor biopsiesTP53-mutated tumorsTumor immune microenvironmentTumor microenvironment componentsT cell expressionImmune cell subsetsTumors of patientsTumor-host interactionsBreast cancer trialsNeoadjuvant trialsComplete responseTN tumorsCD4+Tumor biopsiesCell subsetsPrognostic correlationPrognostic implicationsImmune infiltrationMultiplex immunofluorescenceEfficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis
Chow R, Basu A, Kaur J, Hui D, Im J, Prsic E, Boldt G, Lock M, Eng L, Ng T, Zimmermann C, Scotte F. Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Supportive Care In Cancer 2025, 33: 193. PMID: 39953210, PMCID: PMC11828838, DOI: 10.1007/s00520-025-09251-w.Peer-Reviewed Original ResearchConceptsChemotherapy-induced nausea and vomitingEfficacy of cannabinoidsTHC:CBDMeta-analysisPrevention of chemotherapy-induced nausea and vomitingProphylaxis of chemotherapy-induced nausea and vomitingChemotherapy-induced nausea and vomiting controlControlled trialsCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsRegister of Controlled TrialsNausea and vomitingChemotherapy-induced nauseaMethodsA literature searchCochrane Central RegisterComplete responseRandomized controlled trialsNo vomitingAdjunctive therapyRescue medicationAntiemetic regimensComposite endpointSubgroup analysisCannabinoidSecondary preventionCabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.
Ebrahimi H, Meza L, Dizman N, Barragan-Carrillo R, Li X, Llamas-Quitiquit M, Hsu J, Zengin Z, Castro D, Mercier B, Zugman M, Jaime-Casas S, Chehrazi-Raffle A, Trent J, Lee P, Takahashi M, Dorff T, Caporaso G, Lee K, Pal S. Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study. Journal Of Clinical Oncology 2025, 43: 543-543. DOI: 10.1200/jco.2025.43.5_suppl.543.Peer-Reviewed Original ResearchProgression-free survivalTreatment-related adverse eventsClinical benefitControl armTreatment armsFollow-upImproving progression-free survivalMedian progression-free survivalMetastatic renal cell carcinomaTime of data cutoffTarget lesion sizeTreatment naive patientsMedian follow-upPhase I studyKaplan-Meier methodSecondary clinical endpointsRenal cell carcinomaKarnofsky performance statusFisher's exact testMedian OSSarcomatoid featuresStable diseaseComplete responseData cutoffPapillary histologyMetabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
Saliby R, Labaki C, Jammihal T, Soulati H, Gallegos J, Peris A, McCurry D, Shah V, Poduval D, El Zarif T, El Ahmar N, Nabil Laimon Y, Bagheri Sheshdeh A, Eid M, Krajewski K, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Journal Of Clinical Oncology 2025, 43: 571-571. DOI: 10.1200/jco.2025.43.5_suppl.571.Peer-Reviewed Original ResearchProgression-free survivalImmune checkpoint inhibitorsRenal cell carcinomaComplete responsePartial responseProgressive diseaseWhole-exome sequencingMetabolic gene signatureOverall survivalVEGF inhibitorsCell carcinomaGene set enrichment analysisER patientsSignature scorePatients treated with immune checkpoint inhibitorsResponse to immune checkpoint inhibitionResponse to ICIExceptional responseAdvanced clear cell renal cell carcinomaProgression-free survival predictorsProlonged progression-free survivalMetastatic renal cell carcinomaMultivariate Cox proportional hazards analysisGene signaturePhase III clinical trialsDatopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.
Meric-Bernstam F, Alhalabi O, Lisberg A, Drakaki A, Garmezy B, Kogawa T, Spira A, Salkeni M, Gao X, Tolcher A, Bhave M, Doroshow D, Hoffman-Censits J, Klauss G, Kaga Y, Kakurai Y, Kojima T. Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study. Journal Of Clinical Oncology 2025, 43: 663-663. DOI: 10.1200/jco.2025.43.5_suppl.663.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsBlinded independent central reviewProgression-free survivalDuration of responsePartial responseIndependent central reviewComplete responseConfirmed ORRUrothelial cancerCentral reviewMedian duration of responseMedian progression-free survivalResponse rateImmune checkpoint inhibitorsInterstitial lung disease/pneumonitisTreatment-related AEsMedian follow-upSolid tumor typesAntibody-drug conjugatesPrimary study objectiveCheckpoint inhibitorsDose interruptionPretreated ptsStable diseaseData cutoffCiltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
Popat R, Oriol A, Cavo M, Karlin L, Avivi I, Roeloffzen W, Kim S, Lipe B, Bar N, Horvath N, Spencer A, Min C, Chen D, Li Q, Li K, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Lendvai N, Lengil T, Patel N, Filho O, Florendo E, Lin Y. Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial. Transplantation And Cellular Therapy 2025, 31: s35. DOI: 10.1016/j.jtct.2025.01.047.Peer-Reviewed Original ResearchMinimal residual disease negativityMRD-negativity ratesMinimal residual diseaseProgression-free survivalCilta-cel infusionSustained MRD negativityCilta-celMRD negativityOverall survivalMultiple myelomaSOC armMinimal residual disease positivityMedian progression-free survivalInterim analysisStandard of careMedian OSComplete responseMRD evaluationResidual diseaseCiltacabtagene autoleucelBridging therapyPost-infusionNext-generation sequencingTherapyInfusionOutcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population.
Ganguly A, Paladiya R, Ingawale S, Giri S, Abbagoni V, Thumar J. Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population. Journal Of Clinical Oncology 2025, 43: 208-208. DOI: 10.1200/jco.2025.43.4_suppl.208.Peer-Reviewed Original ResearchTNT groupTotal neoadjuvant therapyLocally advanced rectal cancerAdvanced rectal cancerManagement of locally advanced rectal cancerTumor locationNeoadjuvant therapyConventional therapyRectal cancerCT groupPropensity score matchingLow tumorsHigh tumorNo responsePathologic response to treatmentTreating locally advanced rectal cancerResponse ratePartial response ratePathological response rateScore matchingFisher's exact testResponse to treatmentComplete responseAdjuvant treatmentUnderserved populationsHER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers ☆
Lynce F, Martínez-Sáez O, Walbaum B, Brasó-Maristany F, Waks A, Villagrasa P, Javierre G, Sanfeliu E, Galván P, Paré L, Anderson L, Perou C, Parker J, Vivancos A, DiLullo M, Pernas S, Winer E, Overmoyer B, Mittendorf E, Bueno-Muiño C, Martín M, Prat A, Tolaney S. HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers ☆. ESMO Open 2025, 10: 104100. PMID: 39826476, PMCID: PMC11786065, DOI: 10.1016/j.esmoop.2024.104100.Peer-Reviewed Original ResearchHER2-positive inflammatory breast cancerPathological complete responseInflammatory breast cancerNeoadjuvant systemic therapyNon-IBCBreast cancerSystemic therapyEarly-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancerPredictors of pathologic complete responseHuman epidermal growth factor receptor 2 (HER2)-positive breast cancerIBC cohortIBC statusPathologic complete response rateLow axillary burdenNoninflammatory breast cancerTrastuzumab-based chemotherapyTreatment de-escalationPhase II trialClinical-pathological featuresLong-term prognosisPCR scoreAxillary burdenNeoadjuvant trastuzumabPCR rateComplete response
2024
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial
Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, El-Abed S, Di Cosimo S, Ueno T, Izquierdo M, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C. Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nature Communications 2024, 15: 10402. PMID: 39613746, PMCID: PMC11607438, DOI: 10.1038/s41467-024-54621-3.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, ImmunologicalBiomarkers, TumorBreast NeoplasmsClinical Trials, Phase III as TopicFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedNeoplasm Recurrence, LocalPrognosisRandomized Controlled Trials as TopicReceptor, ErbB-2TrastuzumabTumor MicroenvironmentConceptsHER2-positive breast cancerMolecular subtypesBreast cancerRate of pathological complete responseSensitive to HER2-targeted therapiesClinical trialsRisk of distant recurrenceBreast cancer molecular subtypesPathological complete responseHER2-targeted therapyCancer molecular subtypesPotential clinical implicationsNeoALTTO trialDistant recurrenceComplete responseAdjuvant trastuzumabPrognostic/predictive valueHeterogeneous biologySurvival outcomesI-SPY2Clinical outcomesMicroenvironment featuresGene expression profilesExternal cohortTumorElectrochemotherapy in the Locoregional Treatment of Metastatic Colorectal Liver Metastases: A Systematic Review
Barbieri P, Posa A, Lancellotta V, Madoff D, Maresca A, Cornacchione P, Tagliaferri L, Iezzi R. Electrochemotherapy in the Locoregional Treatment of Metastatic Colorectal Liver Metastases: A Systematic Review. Current Oncology 2024, 31: 7403-7413. PMID: 39590176, PMCID: PMC11592455, DOI: 10.3390/curroncol31110546.Peer-Reviewed Original ResearchConceptsCRC liver metastasesLiver metastasesColorectal cancerComplete responseOverall survivalProgressive diseaseInclusion criteriaResection of CRC liver metastasesTreatment of CRC liver metastasisColorectal cancer liver metastasesSystematic searches of PubMedFrequent liver metastasesMedian overall survivalSecondary liver cancerFollow-up durationColorectal Liver MetastasesMultiple risk factorsCancer-related mortalitySearch of PubMedECT-related complicationsEvidence qualityLocoregional treatmentSurgical resectionIdentified articlesGRADE approach
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply